Research programme: macrophage inhibitory factor antagonists - Cortical/Sanofi GenzymeAlternative Names: COR 100140; Research programme: inflammatory disease therapies - Sanofi Genzyme/Cortical
Latest Information Update: 16 Dec 2016
At a glance
- Originator Cortical; Genzyme Corporation
- Developer Cortical; Sanofi Genzyme
- Class Small molecules
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation